Achilles Therapeutics

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Achilles Therapeutics is dedicated to the research, development, and commercialization of personalized T-cell therapies to cure and treat cancer.

Achilles Therapeutics seeks to bring the power of personalized T-cell therapy to all cancer patients in an accessible and safe manner.

Achilles Therapeutics is the winner of the 2019 ELR Excellence in Translational Research Award and the 2020 Scrip Award for Regulatory Achievement.